CVRx Inc (CVRX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $17.30M
Last updated: Nov 17, 2026 at 11:03 AM ET
CVRx Inc (CVRX) Earnings: Report Dates and Results
CVRX is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, CVRX reported EPS of -$0.52, below the -$0.49 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CVRX has an expected report date of Feb 10, 2027.
CVRX Earnings Call
The latest CVRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, CVRX beat 9, missed 11 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $13.83M, down 5.9% from $14.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.52 | -$0.49 | -$0.53 - -$0.47 | -6.12% | Miss | N/A | 5 | 3 up, 2 down | Nov 5, 2026 | $13.83M |
| Jun 30, 2026 | -$0.53 | -$0.52 | -$0.57 - -$0.46 | -1.92% | Miss | N/A | 7 | 4 up, 1 down | Aug 6, 2026 | $15.71M |
| Mar 31, 2026 | -$0.50 | -$0.50 | -$0.56 - -$0.45 | 0.00% | In line | N/A | 7 | 2 up, 0 down | May 11, 2026 | $14.77M |
| Dec 31, 2025 | -$0.46 | -$0.44 | -$0.48 - -$0.42 | -4.55% | Miss | N/A | 7 | 2 up, 0 down | Feb 12, 2026 | $16.02M |
| Sep 30, 2025 | -$0.49 | -$0.50 | -$0.53 - -$0.47 | +2.00% | Beat | N/A | 7 | 2 up, 4 down | Nov 5, 2025 | $14.69M |
| Jun 30, 2025 | -$0.57 | -$0.52 | -$0.58 - -$0.45 | -9.62% | Miss | N/A | 7 | 3 up, 0 down | Aug 4, 2025 | $13.59M |
| Mar 31, 2025 | -$0.53 | -$0.57 | -$0.71 - -$0.37 | +7.02% | Beat | N/A | 7 | 0 up, 4 down | May 8, 2025 | $12.35M |
| Dec 31, 2024 | -$0.43 | -$0.38 | -$0.42 - -$0.34 | -13.16% | Miss | N/A | 7 | 3 up, 0 down | Feb 4, 2025 | $15.34M |
| Sep 30, 2024 | -$0.57 | -$0.47 | -$0.51 - -$0.42 | -21.28% | Miss | N/A | 7 | 0 up, 0 down | Oct 29, 2024 | $13.37M |
| Jun 30, 2024 | -$0.65 | -$0.55 | -$0.63 - -$0.35 | -18.18% | Miss | N/A | 6 | 0 up, 0 down | Jul 29, 2024 | $11.81M |
| Mar 31, 2024 | -$1.04 | -$0.54 | -$0.60 - -$0.49 | -92.59% | Miss | N/A | 6 | 0 up, 0 down | Apr 30, 2024 | $10.77M |
| Dec 31, 2023 | -$0.44 | -$0.55 | -$0.57 - -$0.49 | +20.00% | Beat | N/A | 6 | 2 up, 0 down | Jan 25, 2024 | $11.30M |
| Sep 30, 2023 | -$0.43 | -$0.58 | -$0.61 - -$0.54 | +25.86% | Beat | N/A | 6 | 0 up, 0 down | Oct 26, 2023 | $10.51M |
| Jun 30, 2023 | -$0.56 | -$0.58 | -$0.63 - -$0.54 | +3.45% | Beat | N/A | 6 | 0 up, 0 down | Jul 25, 2023 | $9.50M |
| Mar 31, 2023 | -$0.55 | -$0.57 | -$0.61 - -$0.50 | +3.51% | Beat | N/A | 6 | 0 up, 0 down | Apr 27, 2023 | $7.98M |
| Dec 31, 2022 | -$0.51 | -$0.56 | -$0.59 - -$0.53 | +8.93% | Beat | N/A | 5 | 0 up, 0 down | Jan 26, 2023 | $7.18M |
| Sep 30, 2022 | -$0.48 | -$0.56 | -$0.59 - -$0.53 | +14.29% | Beat | N/A | 5 | 0 up, 0 down | Nov 1, 2022 | $6.19M |
| Jun 30, 2022 | -$0.54 | -$0.53 | -$0.57 - -$0.51 | -1.89% | Miss | N/A | 5 | 0 up, 0 down | Jul 28, 2022 | $5.03M |
| Mar 31, 2022 | -$0.49 | -$0.49 | -$0.50 - -$0.46 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Apr 25, 2022 | $4.08M |
| Dec 31, 2021 | -$0.52 | -$0.44 | -$0.47 - -$0.43 | -18.18% | Miss | N/A | 4 | 0 up, 0 down | Feb 15, 2022 | $3.66M |
| Sep 30, 2021 | -$0.30 | -$0.40 | -$0.41 - -$0.34 | +25.00% | Beat | N/A | 4 | N/A | Nov 4, 2021 | $3.40M |
| Jun 30, 2021 | -$48.48 | -$21.45 | -$48.48 - -$0.64 | -126.01% | Miss | N/A | 4 | N/A | Aug 4, 2021 | $3.12M |
| Mar 31, 2021 | -$0.70 | -$0.70 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 2, 2021 | $2.86M |
| Dec 31, 2020 | -$0.60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $2.09M |
| Dec 31, 2019 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after -$2.69 the year before. It was -$0.21 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.05 | N/A |
| Dec 31, 2024 | -$2.69 | N/A |
| Dec 31, 2023 | -$1.98 | N/A |
| Dec 31, 2022 | -$2.02 | N/A |
| Dec 31, 2021 | -$50.00 | N/A |
| Dec 31, 2020 | -$0.60 | N/A |
| Dec 31, 2019 | -$0.21 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,357 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,533 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,001 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,892 | 10 | |
| 2025Q3 | Sep 30, 2025 | 5,319 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,978 | 11 | |
| 2025Q1 | Mar 31, 2025 | 5,802 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,422 | 10 |
2026Q3 Earnings Call
Opening remarks
Michael Vallie ICR Healthcare Representative and Call Moderator Good afternoon. Thank you for joining us today for CVRx's Third Quarter 2026 Earnings Conference Call. Joining me on today's call are the company's President and Chief Executive Officer, Kevin Hykes, and Jared Oasheim, our Chief Financial Officer, who will review our financial results. We are also pleased to have with us John Landry, the company's incoming Chief Financial Officer, who joined in October and will assume the CFO role following the filing of our Form 10-Q. The remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings. I would now like to turn the call over to CVRx's President and Chief Executive Officer, Kevin Hykes.
Kevin Hykes President and Chief Executive Officer Thanks, Mark. Good afternoon, and thank you for joining our third quarter 2026 earnings call. We delivered total revenue of $13.8 million in the third quarter, within our guidance range, with a steady gross margin of 87%. Revenue declined 6.1% from the same quarter last year, with U.S. revenue down 4% and Europe down 27%. We continued to stabilize our U.S. sales organization, and a second major payer added a Barostim coverage policy for its Medicare Advantage enrollees. However, the headwinds we have been working through are more impactful and more persistent than we anticipated. While tenure is improving, the impact on performance is taking longer to materialize than we had expected. In part due to these headwinds, I want to give you a fuller picture of what is shaping our business. I will cover three areas: the three headwinds we are facing, which are reimbursement, physician champion turnover, and field execution, and what we are doing about each; what is working in our most stable regions and how we are extending it; and the clinical evidence that is building behind Barostim. I will then introduce our incoming Chief Financial Officer, John Landry, before Jared reviews our financial results. The first headwind is reimbursement. Specifically, the change in behavior from our largest Medicare Advantage payer, which further degraded over the course of the third quarter. Our reimbursement visibility is limited to prior authorizations that we are involved with, which likely represents less than half of all prior authorizations. For those that we handle directly, the approvals that previously occurred within days are now taking three months or longer.
Frequently Asked Questions About CVRX
When is CVRX's next earnings date?
CVRX's next earnings report is expected for Feb 10, 2027.
Did CVRX beat earnings estimates last quarter?
No. CVRX reported EPS of -$0.52 for the quarter ended Sep 30, 2026, below the -$0.49 estimate by 6.12%.
What EPS do analysts expect from CVRX next quarter?
The consensus EPS estimate for CVRX for the quarter ending Dec 31, 2026 is -$0.52 from 9 analysts, with estimates from -$0.53 to -$0.51.
How often does CVRX beat earnings estimates?
CVRX beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -3.29%.
CVRX pages: Overview, Earnings, Forecast, Financials, Competitors